Last10K.com

Ampio Pharmaceuticals, Inc. (AMPE) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Ampio Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1411906 Ticker: AMPE
Document and Entity Information (USD $)
 12 Months Ended
Dec. 31, 2014
Feb. 01, 2015
Jun. 30, 2014
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2014    
Document Fiscal Year Focus 2014    
Document Fiscal Period Focus FY    
Trading Symbol AMPE    
Entity Registrant Name AMPIO PHARMACEUTICALS, INC.    
Entity Central Index Key 0001411906    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Accelerated Filer    
Entity Common Stock, Shares Outstanding   51,972,266dei_EntityCommonStockSharesOutstanding  
Entity Public Float     $ 413,000,000dei_EntityPublicFloat

View differences made from one year to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ampio Pharmaceuticals, Inc..

Continue

Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (parenthetical)
Business, Basis Of Presentation And Merger
Business, Basis Of Presentation And Merger - Additional Information (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Rent Expense (detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (detail)
Common Stock
Common Stock - Additional Information (detail)
Derivative Financial Instruments
Derivative Financial Instruments (tables)
Derivative Financial Instruments - Summary Of Income (expense) Associated With Changes In Fair Value Of Derivative Financial Instruments By Type Of Financing (detail)
Employee Benefit Plan
Equity Instruments
Equity Instruments (tables)
Equity Instruments - Additional Information (detail)
Equity Instruments - Ampio Stock Option Activity (detail)
Equity Instruments - Assumptions Used In Computing Fair Value Of All Options Granted (detail)
Equity Instruments - Luoxis Stock Option Activity (detail)
Equity Instruments - Significant Assumptions (detail)
Equity Instruments - Summary Of Stock Options Outstanding And Exercisable (detail)
Equity Instruments - Summary Of Stock-based Compensation Expense (detail)
Equity Instruments - Vyrix Stock Option Activity (detail)
Equity Instruments - Warrants Issued In Conjunction With Its Senior Convertible Debentures (detail)
Equity Instruments - Weighted Average Fair Value Per Share Granted (detail)
Fair Value Considerations
Formation Of Subsidiaries
Formation Of Subsidiaries - Additional Information (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Deferred Tax Assets And Liabilities (detail)
Income Taxes - Reconciliation Of Effective Tax Rate (detail)
License Agreement/revenue Recognition
License Agreement/revenue Recognition - Additional Information (detail)
Litigation
Litigation - Additional Information (detail)
Related Party Transactions
Related Party Transactions - Additional Information (detail)
Selected Quarterly Data (unaudited)
Selected Quarterly Data (unaudited) (tables)
Selected Quarterly Data (unaudited) - Selected Quarterly Results (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Depreciation Expenses (detail)
Summary Of Significant Accounting Policies - Future Amortization Expense (detail)
Summary Of Significant Accounting Policies - Patents (detail)
Summary Of Significant Accounting Policies - Recorded Amortization Expense (detail)
Summary Of Significant Accounting Policies - Research And Development Costs (detail)
Summary Of Significant Accounting Policies - Schedule Of Fixed Assets (detail)

Material Contracts, Statements, Certifications & more

Ampio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: AMPE
CIK: 1411906
Form Type: 10-K Annual Report
Accession Number: 0001193125-15-059240
Submitted to the SEC: Tue Feb 24 2015 9:04:35 AM EST
Accepted by the SEC: Tue Feb 24 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ampe/0001193125-15-059240.htm